Psychiatry & Neurology Doctors in Grandville, MI Accepting Medicare

5 Psychiatry & Neurology doctors found. Showing 1 - 5

Nan Beth Alt, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 151 44th Street, S.w., Grandville, MI 49418 Phone: 616-457-1889    Fax: 616-457-1891

Dr. Ryan Joseph Yoon, DO Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 4211 Parkway Place Dr Sw, Grandville, MI 49418 Phone: 616-222-3700

Michael Bernard Karluk, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 4211 Parkway Pl Sw, Grandville, MI 49418 Phone: 616-222-3700

Shristi Shah, M.D Psychiatry & Neurology - Child & Adolescent Psychiatry Medicare: Medicare Enrolled Practice Location: 4211 Parkway Pl Sw, Grandville, MI 49418 Phone: 616-222-3700

Dr. Jonathan James Dargo, M.D. Psychiatry & Neurology - Psychiatry Medicare: Accepting Medicare Assignments Practice Location: 4211 Parkway Pl Sw, Grandville, MI 49418 Phone: 616-222-3700

News Archive

Osteoarthritis twice as likely if parents suffer the condition

New research published in the Annals of the Rheumatic Diseases, shows that children whose parents have osteoarthritis of the knee are twice as likely to develop the condition themselves. This research suggests that genetic make-up plays a role in osteoarthritis development.

Scientists reveal how immune cells activate to kill parasitic worms

An international team of researchers including Zissis C. Chroneos, associate professor of pediatrics, and microbiology and immunology at Penn State College of Medicine, reveals how immune cells called macrophages activate to kill parasitic worms.

UC San Diego receives NHLBI 'Program of Excellence in Glycosciences' grant

Scientists at the University of California, San Diego School of Medicine have received a major 7-year, $18 million grant to begin translating emerging discoveries in the field of glycosciences into new discoveries and therapies related to heart, lung and blood diseases.

Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection

MedivirAB is an emerging researchbased specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435, developed by Tibotec Pharmaceuticals, has successfully completed enrollment of three ongoing global phase 3 trials and further reports that all patients are now on TMC435 or active control treatment.

Read more Medical News

› Verified 8 days ago